ConductScience.org, home

Paper21652011

Notch-ing from T-cell to B-cell lymphoid malignancies.

Mirandola L and 5 others. Cancer Lett, 2011. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Notch-ing from T-cell to B-cell lymphoid malignancies. Papers, record 21652011. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21652011

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Notch-ing from T-cell to B-cell lymphoid malignancies.
PubMed
Journal
Cancer Lett
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
0.6
iCite
Revised in PubMed
2022-03-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mirandola LLeonardo
2Comi PPaola
3Cobos EEverardo
4Kast WMW Martin
5Chiriva-Internati MMaurizio
6Chiaramonte RRaffaella

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
B-LymphocytesMajor topic
Hematologic NeoplasmsMajor topic
Receptors, NotchMajor topic
T-LymphocytesMajor topic
Animals
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-Cell
Multiple Myeloma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Stem Cells

Source PubMed

Download CSV of topics

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
39544933Therapeutic potential of natural coumarins in autoimmune diseases with underlying mechanisms.Front Immunol2024https://conductscience.org/library/papers/39544933PubMed
39071599Agrimonolide mitigated DSS-induced colitis by modulating the balance between Treg and Th17 cells through the suppression of the Notch and JAK2/STAT3 signaling pathways.Heliyon2024https://conductscience.org/library/papers/39071599PubMed
35611214Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma.Int J Nanomedicine2022https://conductscience.org/library/papers/35611214PubMed
33918655Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma.Cancers (Basel)2021https://conductscience.org/library/papers/33918655PubMed
32963611Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing.Oncol Lett2020https://conductscience.org/library/papers/32963611PubMed
31582544Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.Haematologica2020https://conductscience.org/library/papers/31582544PubMed
29903986Effect of Notch and PARP Pathways' Inhibition in Leukemic Cells.Cells2018https://conductscience.org/library/papers/29903986PubMed
29104587Notch and its oncogenic activity in human malignancies.Eur Surg2017https://conductscience.org/library/papers/29104587PubMed
27572051Notch 2 signaling contributes to cell growth, anti-apoptosis and metastasis in laryngeal squamous cell carcinoma.Mol Med Rep2016https://conductscience.org/library/papers/27572051PubMed
27463014Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.Oncotarget2016https://conductscience.org/library/papers/27463014PubMed
26848618Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.Oncotarget2016https://conductscience.org/library/papers/26848618PubMed
26308486Notch signaling deregulation in multiple myeloma: A rational molecular target.Oncotarget2015https://conductscience.org/library/papers/26308486PubMed
25257302Notch signaling drives multiple myeloma induced osteoclastogenesis.Oncotarget2014https://conductscience.org/library/papers/25257302PubMed
24968698Genomic characterization of acute leukemias.Med Princ Pract2014https://conductscience.org/library/papers/24968698PubMed
24959528The challenge of targeting notch in hematologic malignancies.Front Pediatr2014https://conductscience.org/library/papers/24959528PubMed
24829804Molecularly targeted therapies in multiple myeloma.Leuk Res Treatment2014https://conductscience.org/library/papers/24829804PubMed
23536563Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma.Cancer Res2013https://conductscience.org/library/papers/23536563PubMed
23354012Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.Leukemia2013https://conductscience.org/library/papers/23354012PubMed
23307030Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.Leukemia2013https://conductscience.org/library/papers/23307030PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21652011

GET https://conductscience.org/api/papers/v1/21652011/authors